Search

Your search keyword '"Delarue, Richard"' showing total 687 results
Start Over Author "Delarue, Richard"
687 results on '"Delarue, Richard"'

1. Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study

Author

Opat, Stephen, Tedeschi, Alessandra, Hu, Bei, Linton, Kim M., McKay, Pamela, Leitch, Sophie, Coleman, Morton, Zinzani, Pier Luigi, Jin, Jie, Sun, Mingyuan, Sobieraj-Teague, Magdalena, Browett, Peter, Ke, Xiaoyan, Thieblemont, Catherine, Ardeshna, Kirit, Bijou, Fontanet, Walker, Patricia, Hawkes, Eliza A., Ho, Shir-Jing, Zhou, Keshu, Liang, Zhiyu, Xu, Jianfeng, Tankersley, Chris, Delarue, Richard, Co, Melannie, and Trotman, Judith

Published
2023
Full Text
View/download PDF

2. Pregnancy in primary immunodeficiency diseases: The PREPI study

Author

Amazzough, Karima, Bertrand, Yves, Boutboul, David, Catherinot, Émilie, Chandesris, Olivia, Cheminant, Morgane, Couderc, Anne, D’Aveni, Maud, Delarue, Richard, Fieschi, Claire, Frenzel, Laurent, Galicier, Lionel, Gardembas, Martine, Goujard, Cécile, Gounot, Romain, Hermine, Olivier, Jaccard, Arnaud, Lambotte, Olivier, Lanternier, Fanny, Levy, Romain, Malphettes, Marion, Marcais, Ambroise, Mouthon, Luc, Oksenhendler, Eric, Perlat, Antoinette, Picard, Capucine, Queyrel, Viviane, Robin, Maris, Suarez, Felipe, Viallard, Jean François, Mallart, Elise, Françoise, Ugo, Driessen, Marine, Blanche, Stéphane, Lortholary, Olivier, Lefort, Agnès, Caseris, Marion, Fischer, Alain, Mahlaoui, Nizar, and Charlier, Caroline

Published
2023
Full Text
View/download PDF

3. Outcomes of older patients with diffuse large B-cell lymphoma treated with R-CHOP: 10-year follow-up of the LNH03-6B trial

Author

Camus, Vincent, Belot, Aurélien, Oberic, Lucie, Sibon, David, Ghesquières, Hervé, Thieblemont, Catherine, Fruchart, Christophe, Casasnovas, Olivier, Michot, Jean-Marie, Molina, Thierry Jo, Bosly, André, Joubert, Clémentine, Haioun, Corinne, Nicolas-Virelizier, Emmanuelle, Feugier, Pierre, Fitoussi, Olivier, Delarue, Richard, and Tilly, Hervé

Published
2022
Full Text
View/download PDF

5. Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial

Author

Camus, Vincent, primary, Thieblemont, Catherine, additional, Gaulard, Philippe, additional, Cheminant, Morgane, additional, Casasnovas, Rene-Olivier, additional, Ysebaert, Loïc, additional, Damaj, Gandhi Laurent, additional, Guidez, Stéphanie, additional, Pica, Gian Matteo, additional, Kim, Won Seog, additional, Lim, Soon Thye, additional, Andre, Marc, additional, Gutiérrez, Norma, additional, Penarrubia, Maria Jesus, additional, Staber, Philipp B., additional, Trotman, Judith, additional, Hüttmann, Andreas, additional, Stefoni, Vittorio, additional, Tucci, Alessandra, additional, Fogarty, Patrick, additional, Farhat, Hassan, additional, Abraham, Julie, additional, Abarah, Wajed, additional, Belmecheri, Fatiha, additional, Ribrag, Vincent, additional, Delfau-Larue, Marie-Helene, additional, Cottereau, Anne-Ségolène, additional, Itti, Emmanuel, additional, Li, Ju, additional, Delarue, Richard, additional, de Leval, Laurence, additional, Morschhauser, Franck, additional, and Bachy, Emmanuel, additional

Published
2024
Full Text
View/download PDF

7. GAPDH Expression Predicts the Response to R-CHOP, the Tumor Metabolic Status, and the Response of DLBCL Patients to Metabolic Inhibitors

Author

Chiche, Johanna, Reverso-Meinietti, Julie, Mouchotte, Annabelle, Rubio-Patiño, Camila, Mhaidly, Rana, Villa, Elodie, Bossowski, Jozef P., Proics, Emma, Grima-Reyes, Manuel, Paquet, Agnès, Fragaki, Konstantina, Marchetti, Sandrine, Briere, Josette, Ambrosetti, Damien, Michiels, Jean-François, Molina, Thierry Jo, Copie-Bergman, Christiane, Lehmann-Che, Jacqueline, Peyrottes, Isabelle, Peyrade, Frederic, de Kerviler, Eric, Taillan, Bruno, Garnier, Georges, Verhoeyen, Els, Paquis-Flucklinger, Véronique, Shintu, Laetitia, Delwail, Vincent, Delpech-Debiais, Celine, Delarue, Richard, Bosly, André, Petrella, Tony, Brisou, Gabriel, Nadel, Bertrand, Barbry, Pascal, Mounier, Nicolas, Thieblemont, Catherine, and Ricci, Jean-Ehrland

Published
2019
Full Text
View/download PDF

8. ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma

Author

Zinzani, Pier Luigi, primary, Mayer, Jiří, additional, Flowers, Christopher R., additional, Bijou, Fontanet, additional, De Oliveira, Ana C., additional, Song, Yuqin, additional, Zhang, Qingyuan, additional, Merli, Michele, additional, Bouabdallah, Krimo, additional, Ganly, Peter, additional, Zhang, Huilai, additional, Johnson, Roderick, additional, Martín García-Sancho, Alejandro, additional, Provencio Pulla, Mariano, additional, Trněný, Marek, additional, Yuen, Sam, additional, Tilly, Herve, additional, Kingsley, Edwin, additional, Tumyan, Gayane, additional, Assouline, Sarit E., additional, Auer, Rebecca, additional, Ivanova, Elena, additional, Kim, Pil, additional, Huang, Sha, additional, Delarue, Richard, additional, and Trotman, Judith, additional

Published
2023
Full Text
View/download PDF

9. PB2276: MAHOGANY: A PHASE 3 TRIAL OF ZANUBRUTINIB PLUS ANTI-CD20 ANTIBODIES VS LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMA

Author

Silvestre, Antonio Salar, primary, Trotman, Judith, additional, Sarkozy, Clementine, additional, Song, Yuqin, additional, Sehn, Laurie H., additional, Nastoupil, Loretta J., additional, Zhang, Wanhua, additional, Fustier, Pierre, additional, Delarue, Richard, additional, and Zinzani, Pier Luigi, additional

Published
2023
Full Text
View/download PDF

10. P1084: LONG-TERM EFFICACY AND SAFETY OF ZANUBRUTINIB (ZANU) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) MARGINAL ZONE LYMPHOMA (MZL): FINAL ANALYSIS OF THE MAGNOLIA (BGB-3111-214) TRIAL

Author

Opat, Stephen, primary, Tedeschi, Alessandra, additional, Hu, Bei, additional, Linton, Kim, additional, Mckay, Pam, additional, Leitch, Sophie, additional, Jin, Jie, additional, Sun, Mingyuan, additional, Sobieraj-Teague, Magdalena, additional, Luigi Zinzani, Pier, additional, Browett, Peter, additional, Thieblemont, Catherine, additional, Marina Liberati, Anna, additional, Bachy, Emmanuel, additional, Cavallo, Federica, additional, Costello, Régis, additional, Iyengar, Sunil, additional, Marasca, Roberto, additional, Mociková, Heidi, additional, Seok Kim, Jin, additional, Talaulikar, Dipti, additional, Liang, Zhiyu, additional, Xu, Jianfeng, additional, Tankersley, Chris, additional, Delarue, Richard, additional, Co, Melannie, additional, and Trotman, Judith, additional

Published
2023
Full Text
View/download PDF

11. P1080: ZANUBRUTINIB PLUS OBINUTUZUMAB VERSUS OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: UPDATED ANALYSIS OF THE ROSEWOOD STUDY

Author

Trotman, Judith, primary, Luigi Zinzani, Pier, additional, Mayer, Jiri, additional, Flowers, Chris, additional, Bijou, Fontanet, additional, Carla Oliveira, Ana, additional, Bouabdallah, Kamal, additional, Johnson, Rod, additional, Martin Garcia-Sancho, Alejandro, additional, Provencio Pulla, Mariano, additional, Trneny, Marek, additional, Tilly, Hervé, additional, Jurczak, Wojciech, additional, Ivanova, Elena, additional, Kim, Pil, additional, Greenbaum, Adam, additional, Huang, Sha, additional, Delarue, Richard, additional, and Auer, Rebecca, additional

Published
2023
Full Text
View/download PDF

12. PB1926: EFFICACY AND SAFETY OF ONCE DAILY (QD) VS TWICE DAILY (BID) ZANUBRUTINIB FOR PATIENTS WITH VARIOUS B-CELL MALIGNANCIES: A COMPARATIVE SUMMARY OF CLINICAL DATA AND EXPOSURE-RESPONSE ANALYSES

Author

Tam, Constantine, primary, Shadman, Mazyar, additional, Sharman, Jeff, additional, Cull, Gavin, additional, Phillips, Tycel, additional, Trotman, Judith, additional, Cohen, Aileen, additional, Allewelt, Heather, additional, Crescenzo, Rocco, additional, Delarue, Richard, additional, Zhang, Heather, additional, Tariq, Bilal, additional, Sahasranaman, Sri, additional, Ou, Ying C, additional, and Flinn, Ian W, additional

Published
2023
Full Text
View/download PDF

14. ABVD or BEACOPPbaseline along with involved-field radiotherapy in early-stage Hodgkin Lymphoma with risk factors: Results of the European Organisation for Research and Treatment of Cancer (EORTC)–Groupe d'Étude des Lymphomes de l'Adulte (GELA) H9-U intergroup randomised trial

Author

Fermé, Christophe, Thomas, José, Brice, Pauline, Casasnovas, Olivier, Vranovsky, Andrej, Bologna, Serge, Lugtenburg, Pieternella J., Bouabdallah, Réda, Carde, Patrice, Sebban, Catherine, Eghbali, Houchingue, Salles, Gilles, van Imhoff, Gustaaf W., Thyss, Antoine, Noordijk, Evert M., Reman, Oumédaly, Lybeert, Marnix L.M., Janvier, Maud, Spina, Michele, Audhuy, Bruno, Raemaekers, John M.M., Delarue, Richard, Anglaret, Bruno, de Weerdt, Okke, Marjanovic, Zora, Tersteeg, Robbert J.H.A., de Jong, Daphne, Brière, Josette, and Henry-Amar, Michel

Published
2017
Full Text
View/download PDF

15. Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group

Author

Peyrade, Frédéric, Bologna, Serge, Delwail, Vincent, Emile, Jean François, Pascal, Laurent, Fermé, Christophe, Schiano, Jean-Marc, Coiffier, Bertrand, Corront, Bernadette, Farhat, Hassan, Fruchart, Christophe, Ghesquieres, Herve, Macro, Margaret, Tilly, Hervé, Choufi, Bachra, Delarue, Richard, Fitoussi, Olivier, Gabarre, Jean, Haioun, Corinne, and Jardin, Fabrice

Published
2017
Full Text
View/download PDF

17. Supplementary Data from Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P–Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases

Author

Dubois, Sydney, primary, Viailly, Pierre-Julien, primary, Bohers, Elodie, primary, Bertrand, Philippe, primary, Ruminy, Philippe, primary, Marchand, Vinciane, primary, Maingonnat, Catherine, primary, Mareschal, Sylvain, primary, Picquenot, Jean-Michel, primary, Penther, Dominique, primary, Jais, Jean-Philippe, primary, Tesson, Bruno, primary, Peyrouze, Pauline, primary, Figeac, Martin, primary, Desmots, Fabienne, primary, Fest, Thierry, primary, Haioun, Corinne, primary, Lamy, Thierry, primary, Copie-Bergman, Christiane, primary, Fabiani, Bettina, primary, Delarue, Richard, primary, Peyrade, Frédéric, primary, André, Marc, primary, Ketterer, Nicolas, primary, Leroy, Karen, primary, Salles, Gilles, primary, Molina, Thierry J., primary, Tilly, Hervé, primary, and Jardin, Fabrice, primary

Published
2023
Full Text
View/download PDF

18. Table S5. Cohort variants. from Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P–Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases

Author

Dubois, Sydney, primary, Viailly, Pierre-Julien, primary, Bohers, Elodie, primary, Bertrand, Philippe, primary, Ruminy, Philippe, primary, Marchand, Vinciane, primary, Maingonnat, Catherine, primary, Mareschal, Sylvain, primary, Picquenot, Jean-Michel, primary, Penther, Dominique, primary, Jais, Jean-Philippe, primary, Tesson, Bruno, primary, Peyrouze, Pauline, primary, Figeac, Martin, primary, Desmots, Fabienne, primary, Fest, Thierry, primary, Haioun, Corinne, primary, Lamy, Thierry, primary, Copie-Bergman, Christiane, primary, Fabiani, Bettina, primary, Delarue, Richard, primary, Peyrade, Frédéric, primary, André, Marc, primary, Ketterer, Nicolas, primary, Leroy, Karen, primary, Salles, Gilles, primary, Molina, Thierry J., primary, Tilly, Hervé, primary, and Jardin, Fabrice, primary

Published
2023
Full Text
View/download PDF

19. Table S2. Cell of origin according to MYD88 mutations. from Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P–Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases

Author

Dubois, Sydney, primary, Viailly, Pierre-Julien, primary, Bohers, Elodie, primary, Bertrand, Philippe, primary, Ruminy, Philippe, primary, Marchand, Vinciane, primary, Maingonnat, Catherine, primary, Mareschal, Sylvain, primary, Picquenot, Jean-Michel, primary, Penther, Dominique, primary, Jais, Jean-Philippe, primary, Tesson, Bruno, primary, Peyrouze, Pauline, primary, Figeac, Martin, primary, Desmots, Fabienne, primary, Fest, Thierry, primary, Haioun, Corinne, primary, Lamy, Thierry, primary, Copie-Bergman, Christiane, primary, Fabiani, Bettina, primary, Delarue, Richard, primary, Peyrade, Frédéric, primary, André, Marc, primary, Ketterer, Nicolas, primary, Leroy, Karen, primary, Salles, Gilles, primary, Molina, Thierry J., primary, Tilly, Hervé, primary, and Jardin, Fabrice, primary

Published
2023
Full Text
View/download PDF

20. Table S7. Immunohistochemical markers and gene rearrangements according to MYD88 variants. from Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P–Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases

Author

Dubois, Sydney, primary, Viailly, Pierre-Julien, primary, Bohers, Elodie, primary, Bertrand, Philippe, primary, Ruminy, Philippe, primary, Marchand, Vinciane, primary, Maingonnat, Catherine, primary, Mareschal, Sylvain, primary, Picquenot, Jean-Michel, primary, Penther, Dominique, primary, Jais, Jean-Philippe, primary, Tesson, Bruno, primary, Peyrouze, Pauline, primary, Figeac, Martin, primary, Desmots, Fabienne, primary, Fest, Thierry, primary, Haioun, Corinne, primary, Lamy, Thierry, primary, Copie-Bergman, Christiane, primary, Fabiani, Bettina, primary, Delarue, Richard, primary, Peyrade, Frédéric, primary, André, Marc, primary, Ketterer, Nicolas, primary, Leroy, Karen, primary, Salles, Gilles, primary, Molina, Thierry J., primary, Tilly, Hervé, primary, and Jardin, Fabrice, primary

Published
2023
Full Text
View/download PDF

21. Supplementary Data from Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study

Author

Dubois, Sydney, primary, Viailly, Pierre-Julien, primary, Mareschal, Sylvain, primary, Bohers, Elodie, primary, Bertrand, Philippe, primary, Ruminy, Philippe, primary, Maingonnat, Catherine, primary, Jais, Jean-Philippe, primary, Peyrouze, Pauline, primary, Figeac, Martin, primary, Molina, Thierry J., primary, Desmots, Fabienne, primary, Fest, Thierry, primary, Haioun, Corinne, primary, Lamy, Thierry, primary, Copie-Bergman, Christiane, primary, Brière, Josette, primary, Petrella, Tony, primary, Canioni, Danielle, primary, Fabiani, Bettina, primary, Coiffier, Bertrand, primary, Delarue, Richard, primary, Peyrade, Frédéric, primary, Bosly, André, primary, André, Marc, primary, Ketterer, Nicolas, primary, Salles, Gilles, primary, Tilly, Hervé, primary, Leroy, Karen, primary, and Jardin, Fabrice, primary

Published
2023
Full Text
View/download PDF

22. Table S10. Clinical characteristics of patients with CNS relapse. from Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P–Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases

Author

Dubois, Sydney, primary, Viailly, Pierre-Julien, primary, Bohers, Elodie, primary, Bertrand, Philippe, primary, Ruminy, Philippe, primary, Marchand, Vinciane, primary, Maingonnat, Catherine, primary, Mareschal, Sylvain, primary, Picquenot, Jean-Michel, primary, Penther, Dominique, primary, Jais, Jean-Philippe, primary, Tesson, Bruno, primary, Peyrouze, Pauline, primary, Figeac, Martin, primary, Desmots, Fabienne, primary, Fest, Thierry, primary, Haioun, Corinne, primary, Lamy, Thierry, primary, Copie-Bergman, Christiane, primary, Fabiani, Bettina, primary, Delarue, Richard, primary, Peyrade, Frédéric, primary, André, Marc, primary, Ketterer, Nicolas, primary, Leroy, Karen, primary, Salles, Gilles, primary, Molina, Thierry J., primary, Tilly, Hervé, primary, and Jardin, Fabrice, primary

Published
2023
Full Text
View/download PDF

23. Table S1. Clinical and immunohistochemical data according to MYD88 mutation status. from Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P–Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases

Author

Dubois, Sydney, primary, Viailly, Pierre-Julien, primary, Bohers, Elodie, primary, Bertrand, Philippe, primary, Ruminy, Philippe, primary, Marchand, Vinciane, primary, Maingonnat, Catherine, primary, Mareschal, Sylvain, primary, Picquenot, Jean-Michel, primary, Penther, Dominique, primary, Jais, Jean-Philippe, primary, Tesson, Bruno, primary, Peyrouze, Pauline, primary, Figeac, Martin, primary, Desmots, Fabienne, primary, Fest, Thierry, primary, Haioun, Corinne, primary, Lamy, Thierry, primary, Copie-Bergman, Christiane, primary, Fabiani, Bettina, primary, Delarue, Richard, primary, Peyrade, Frédéric, primary, André, Marc, primary, Ketterer, Nicolas, primary, Leroy, Karen, primary, Salles, Gilles, primary, Molina, Thierry J., primary, Tilly, Hervé, primary, and Jardin, Fabrice, primary

Published
2023
Full Text
View/download PDF

24. Table S6. Cohort copy number variations. from Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P–Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases

Author

Dubois, Sydney, primary, Viailly, Pierre-Julien, primary, Bohers, Elodie, primary, Bertrand, Philippe, primary, Ruminy, Philippe, primary, Marchand, Vinciane, primary, Maingonnat, Catherine, primary, Mareschal, Sylvain, primary, Picquenot, Jean-Michel, primary, Penther, Dominique, primary, Jais, Jean-Philippe, primary, Tesson, Bruno, primary, Peyrouze, Pauline, primary, Figeac, Martin, primary, Desmots, Fabienne, primary, Fest, Thierry, primary, Haioun, Corinne, primary, Lamy, Thierry, primary, Copie-Bergman, Christiane, primary, Fabiani, Bettina, primary, Delarue, Richard, primary, Peyrade, Frédéric, primary, André, Marc, primary, Ketterer, Nicolas, primary, Leroy, Karen, primary, Salles, Gilles, primary, Molina, Thierry J., primary, Tilly, Hervé, primary, and Jardin, Fabrice, primary

Published
2023
Full Text
View/download PDF

25. Supplementary Figures from Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P–Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases

Author

Dubois, Sydney, primary, Viailly, Pierre-Julien, primary, Bohers, Elodie, primary, Bertrand, Philippe, primary, Ruminy, Philippe, primary, Marchand, Vinciane, primary, Maingonnat, Catherine, primary, Mareschal, Sylvain, primary, Picquenot, Jean-Michel, primary, Penther, Dominique, primary, Jais, Jean-Philippe, primary, Tesson, Bruno, primary, Peyrouze, Pauline, primary, Figeac, Martin, primary, Desmots, Fabienne, primary, Fest, Thierry, primary, Haioun, Corinne, primary, Lamy, Thierry, primary, Copie-Bergman, Christiane, primary, Fabiani, Bettina, primary, Delarue, Richard, primary, Peyrade, Frédéric, primary, André, Marc, primary, Ketterer, Nicolas, primary, Leroy, Karen, primary, Salles, Gilles, primary, Molina, Thierry J., primary, Tilly, Hervé, primary, and Jardin, Fabrice, primary

Published
2023
Full Text
View/download PDF

26. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network

Author

Hermine, Olivier, Hoster, Eva, Walewski, Jan, Bosly, André, Stilgenbauer, Stephan, Thieblemont, Catherine, Szymczyk, Michal, Bouabdallah, Reda, Kneba, Michael, Hallek, Michael, Salles, Gilles, Feugier, Pierre, Ribrag, Vincent, Birkmann, Josef, Forstpointner, Roswitha, Haioun, Corinne, Hänel, Mathias, Casasnovas, René Olivier, Finke, Jürgen, Peter, Norma, Bouabdallah, Kamal, Sebban, Catherine, Fischer, Thomas, Dührsen, Ulrich, Metzner, Bernd, Maschmeyer, Georg, Kanz, Lothar, Schmidt, Christian, Delarue, Richard, Brousse, Nicole, Klapper, Wolfram, Macintyre, Elizabeth, Delfau-Larue, Marie-Hélène, Pott, Christiane, Hiddemann, Wolfgang, Unterhalt, Michael, and Dreyling, Martin

Published
2016
Full Text
View/download PDF

27. Long-Term Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory (R/R) Marginal Zone Lymphoma (MZL): Final Analysis of the Magnolia (BGB-3111-214) Trial

Author

Opat, Stephen, primary, Tedeschi, Alessandra, additional, Hu, Bei, additional, Linton, Kim M, additional, McKay, Pamela, additional, Chan, Henry, additional, Jin, Jie, additional, Sun, Mingyuan, additional, Sobieraj-Teague, Magdalena, additional, Zinzani, Pier Luigi, additional, Browett, Peter, additional, Ke, Xiaoyan, additional, Portell, Craig A., additional, Thieblemont, Catherine, additional, Ardeshna, Kirit, additional, Bijou, Fontanet, additional, Walker, Patricia, additional, Hawkes, Eliza A., additional, Ho, Shir-Jing, additional, Zhou, Keshu, additional, Liang, Zhiyu, additional, Xu, Jianfeng, additional, Tankersley, Chris, additional, Delarue, Richard, additional, Co, Melannie, additional, and Trotman, Judith, additional

Published
2023
Full Text
View/download PDF

28. MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study

Author

Copie-Bergman, Christiane, Cuillière-Dartigues, Peggy, Baia, Maryse, Briere, Josette, Delarue, Richard, Canioni, Danielle, Salles, Gilles, Parrens, Marie, Belhadj, Karim, Fabiani, Bettina, Recher, Christian, Petrella, Tony, Ketterer, Nicolas, Peyrade, Frederic, Haioun, Corinne, Nagel, Inga, Siebert, Reiner, Jardin, Fabrice, Leroy, Karen, Jais, Jean-Philippe, Tilly, Herve, Molina, Thierry Jo, and Gaulard, Philippe

Published
2015
Full Text
View/download PDF

29. Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Final Analysis of a Lysa Multicenter, Phase II Study. "the TOTAL Trial"

Author

Tournilhac, Olivier, primary, Lecolant, Solene, additional, Hacini, Maya, additional, Bouabdallah, Krimo, additional, Bailly, Sebastien, additional, Laribi, Kamel, additional, Belmondo, Thibaut, additional, Maerevoet, Marie, additional, Ysebaert, Loic, additional, Guidez, Stéphanie, additional, Le Gouill, Steven, additional, Bonnet, Christophe, additional, Andre, Marc, additional, Dupuis, Jehan, additional, Thieblemont, Catherine, additional, Bachy, Emmanuel, additional, Daguindau, Nicolas, additional, Morschhauser, Franck, additional, Tricot, Sabine, additional, Feugier, Pierre, additional, Banos, Anne, additional, Lamy, Thierry, additional, Chauchet, Adrien, additional, Gyan, Emmanuel, additional, Cartron, Guillaume, additional, Farhat, Hassan, additional, Camus, Vincent, additional, Drenou, Bernard, additional, Zerazhi, Hacene, additional, Sibon, David, additional, Nicolas-Virelizier, Emmanuelle, additional, Delette, Caroline, additional, Snauwaert, Sylvia, additional, Straetmans, Nicole, additional, Delarue, Richard, additional, Parrens, Marie, additional, Griolet, Samuel, additional, Gaulard, Philippe, additional, Delfau-Larue, Marie-Helene, additional, De Leval, Laurence, additional, and Damaj, Gandhi Laurent, additional

Published
2022
Full Text
View/download PDF

30. Long-Term Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory (R/R) Marginal Zone Lymphoma (MZL): Final Analysis of the Magnolia (BGB-3111-214) Trial

Author

Opat, Stephen, primary, Tedeschi, Alessandra, additional, Hu, Bei, additional, Linton, Kim M., additional, McKay, Pamela, additional, Chan, Henry, additional, Jin, Jie, additional, Sun, Mingyuan, additional, Sobieraj-Teague, Magdalena, additional, Zinzani, Pier Luigi, additional, Browett, Peter J., additional, Ke, Xiaoyan, additional, Portell, Craig A., additional, Thieblemont, Catherine, additional, Ardeshna, Kirit, additional, Bijou, Fontanet, additional, Walker, Patricia, additional, Hawkes, Eliza, additional, Ho, Shir-Jing, additional, Zhou, Keshu, additional, Liang, Zhiyu, additional, Xu, Jianfeng, additional, Tankersley, Chris, additional, Delarue, Richard, additional, Co, Melannie, additional, and Trotman, Judith, additional

Published
2022
Full Text
View/download PDF

31. A susceptibility locus for classical Hodgkin lymphoma at 8q24 near MYC/PVT1 predicts patient outcome in two independent cohorts

Author

Ghesquières, Hervé, Larrabee, Beth R., Casasnovas, Olivier, Maurer, Matthew J., McKay, James D., Ansell, Stephen M., Montgomery, Dorothy, Asmann, Yan W., Farrell, Katrina, Verney, Aurélie, Slager, Susan L., Allmer, Cristine, Perrot, Aurore, Delarue, Richard, Habermann, Thomas M., Dupuis, Jehan, Link, Brian K., Canioni, Danielle, Dogan, Ahmet, Cozen, Wendy, Jarrett, Ruth F., Cerhan, James R., and Salles, Gilles

Published
2018
Full Text
View/download PDF

32. Durvalumab as monotherapy and in combination therapy in patients with lymphoma or chronic lymphocytic leukemia: The FUSION NHL 001 trial

Author

Casulo, Carla, primary, Santoro, Armando, additional, Cartron, Guillaume, additional, Ando, Kiyoshi, additional, Munoz, Javier, additional, Le Gouill, Steven, additional, Izutsu, Koji, additional, Rule, Simon, additional, Lugtenburg, Pieternella, additional, Ruan, Jia, additional, Arcaini, Luca, additional, Casadebaig, Marie‐Laure, additional, Fox, Brian, additional, Kilavuz, Nurgul, additional, Rettby, Nils, additional, Dell'Aringa, Justine, additional, Taningco, Lilia, additional, Delarue, Richard, additional, Czuczman, Myron, additional, and Witzig, Thomas, additional

Published
2022
Full Text
View/download PDF

33. Zanubrutinib plus obinutuzumab (ZO) versus obinutuzumab (O) monotherapy in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Primary analysis of the phase 2 randomized ROSEWOOD trial.

Author

Zinzani, Pier Luigi, primary, Mayer, Jiří, additional, Auer, Rebecca, additional, Bijou, Fontanet, additional, de Oliveira, Ana C., additional, Flowers, Christopher, additional, Merli, Michele, additional, Bouabdallah, Krimo, additional, Ganly, Peter S., additional, Johnson, Roderick, additional, Yuen, Sam, additional, Kingsley, Ed, additional, Tumyan, Gayane, additional, Assouline, Sarit E., additional, Ivanova, Elena, additional, Kim, Pil, additional, Huang, Jane, additional, Delarue, Richard, additional, and Trotman, Judith, additional

Published
2022
Full Text
View/download PDF

34. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial

Author

Delarue, Richard, Tilly, Hervé, Mounier, Nicolas, Petrella, Tony, Salles, Gilles, Thieblemont, Catherine, Bologna, Serge, Ghesquières, Hervé, Hacini, Maya, Fruchart, Christophe, Ysebaert, Loïc, Fermé, Christophe, Casasnovas, Olivier, Van Hoof, Achiel, Thyss, Antoine, Delmer, Alain, Fitoussi, Olivier, Molina, Thierry Jo, Haioun, Corinne, and Bosly, André

Published
2013
Full Text
View/download PDF

36. Outcomes of elderly diffuse large B-cell lymphoma patients treated with R-CHOP: 10-year follow-up of the LNH03-6B trial.

Author

UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Camus, Vincent, Belot, Aurelien, Obéric, Lucie, Sibon, David, Ghesquieres, Herve, Thieblemont, Catherine, Fruchart, Christophe, Casasnovas, Olivier, Michot, Jean-Marie, Molina, Thierry, Bosly, André, Joubert, Clémentine, Haioun, Corinne, Nicolas-Virelizier, Emmanuelle, Feugier, Pierre, Fitoussi, Olivier, Delarue, Richard, Tilly, Herve, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Camus, Vincent, Belot, Aurelien, Obéric, Lucie, Sibon, David, Ghesquieres, Herve, Thieblemont, Catherine, Fruchart, Christophe, Casasnovas, Olivier, Michot, Jean-Marie, Molina, Thierry, Bosly, André, Joubert, Clémentine, Haioun, Corinne, Nicolas-Virelizier, Emmanuelle, Feugier, Pierre, Fitoussi, Olivier, Delarue, Richard, and Tilly, Herve

Abstract

The LNH03-6B trial was a phase 3 randomized trial evaluating the efficacy of first-Line R-CHOP delivered every 2 weeks (R-CHOP14) or 3 weeks (R-CHOP21) in diffuse large B-cell lymphoma patients aged 60-80 years with an age-adjusted IPI score greater than or equal to 1 (registered as NCT00144755). We implemented a prospective long-term follow-up (LTFU) program at the end of this trial. The primary endpoints were progression-free survival (PFS) and Overall survival (OS). Relapse patterns and PFS/OS after the first progression (PFS2/OS2) were secondary endpoints. LNH03-6B was registered with ClinicalTrial.gov number NCT00144755. In the LNH03-6B trial, 304 and 296 patients were assigned to receive 8 cycles of R-CHOP14 or R-CHOP21, respectively. LTFU data were investigated for 256/384 (67%) patients who were still alive at the primary analysis. With a median follow-up of 10.1 years, 213 patients progressed, and 140 patients died without progression. The ten-year PFS was 40.4% (95% CI: 35.9-44.9). Ten-year OS was based on 302 deaths and estimated at 50% (43-56). One hundred and five of the 213 patients (49%) progressed after second-line therapy, and 77 patients died without a second progression (36%). The 1-year PFS2 and 1-year OS2 were estimated at 37.9% [31.4-44.5] and 55.8% [48.8-62.2], respectively. Ten years after randomization, the outcomes of patients treated for DLBCL were similar according to PFS and OS between the RCHOP-14 and R-CHOP21 groups. Progression/relapse led to poor prognosis after second-line chemotherapy in the pre-CAR-T era. Novel approaches in first-line and alternative treatments in second-line treatments are warranted in this population.

Published
2022

37. Outcomes for HIV-associated diffuse large B-cell lymphoma in the modern combined antiretroviral therapy era

Author

Besson, Caroline, Lancar, Remi, Prevot, Sophie, Algarte-Genin, Michele, Delobel, Pierre, Bonnet, Fabrice, Meyohas, Marie-Caroline, Partisani, Marialuisa, Oberic, Lucie, Gabarre, Jean, Goujard, Cécile, Boue, François, Coppo, Paul, Costello, Regis, Hendel-Chavez, Houria, Mekerri, Nawel, Dos Santos, Gabriella, Recher, Christian, Delarue, Richard, Casasnovas, Rene-Olivier, Taoufik, Yassine, Mounier, Nicolas, and Costagliola, Dominique

Published
2017
Full Text
View/download PDF

38. Management of central nervous system involvement in chronic lymphocytic leukaemia: a retrospective cohort of 30 patients

Author

Wanquet, Anne, Birsen, Rudy, Bonnet, Charlotte, Boubaya, Marouane, Choquet, Sylvain, Dupuis, Jehan, Lepretre, Stephane, Re, Daniel, Fahri, Jonathan, Michallet, AnneSophie, Ysebaert, Loïc, Lemal, Richard, Lamy, Thierry, Delarue, Richard, Troussard, Xavier, Cymbalista, Florence, Levy, Vincent, Dietrich, PierreYves, Leblond, Veronique, and AurranSchleinitz, Therese

Published
2017
Full Text
View/download PDF

39. Outcomes of elderly diffuse large B-cell lymphoma patients treated with R-CHOP: 10-year follow-up of the LNH03-6B trial

Author

Camus, Vincent, Belot, Aurelien, Obéric, Lucie, Sibon, David, Ghesquieres, Herve, Thieblemont, Catherine, Fruchart, Christophe, Casasnovas, Olivier, Michot, Jean-Marie, Molina, Thierry, Bosly, Andre, Joubert, Clémentine, Haioun, Corinne, Nicolas-Virelizier, Emmanuelle, Feugier, Pierre, Fitoussi, Olivier, Delarue, Richard, Tilly, Herve, UCL - SSS/IREC/MONT - Pôle Mont Godinne, and UCL - (MGD) Service d'hématologie

Abstract

The LNH03-6B trial was a phase 3 randomized trial evaluating the efficacy of first-Line R-CHOP delivered every 2 weeks (R-CHOP14) or 3 weeks (R-CHOP21) in diffuse large B-cell lymphoma patients aged 60-80 years with an age-adjusted IPI score greater than or equal to 1 (registered as NCT00144755). We implemented a prospective long-term follow-up (LTFU) program at the end of this trial. The primary endpoints were progression-free survival (PFS) and Overall survival (OS). Relapse patterns and PFS/OS after the first progression (PFS2/OS2) were secondary endpoints. LNH03-6B was registered with ClinicalTrial.gov number NCT00144755. In the LNH03-6B trial, 304 and 296 patients were assigned to receive 8 cycles of R-CHOP14 or R-CHOP21, respectively. LTFU data were investigated for 256/384 (67%) patients who were still alive at the primary analysis. With a median follow-up of 10.1 years, 213 patients progressed, and 140 patients died without progression. The ten-year PFS was 40.4% (95% CI: 35.9-44.9). Ten-year OS was based on 302 deaths and estimated at 50% (43-56). One hundred and five of the 213 patients (49%) progressed after second-line therapy, and 77 patients died without a second progression (36%). The 1-year PFS2 and 1-year OS2 were estimated at 37.9% [31.4-44.5] and 55.8% [48.8-62.2], respectively. Ten years after randomization, the outcomes of patients treated for DLBCL were similar according to PFS and OS between the RCHOP-14 and R-CHOP21 groups. Progression/relapse led to poor prognosis after second-line chemotherapy in the pre-CAR-T era. Novel approaches in first-line and alternative treatments in second-line treatments are warranted in this population.

Published
2022

40. 90Y Ibritumomab Tiuxetan (Zevalin) Combined With BEAM (Z -BEAM) Conditioning Regimen Plus Autologous Stem Cell Transplantation in Relapsed or Refractory Low-grade CD20-positive B-cell Lymphoma. A GELA Phase II Prospective Study

Author

Decaudin, Didier, Mounier, Nicolas, Tilly, Hervé, Ribrag, Vincent, Ghesquières, Hervé, Bouabdallah, Krimo, Morschhauser, Franck, Coiffier, Bertrand, Le Gouill, Steven, Bologna, Serge, Delarue, Richard, Huynh, Anne, Bosly, André, Brière, Josette, and Gisselbrecht, Christian

Published
2011
Full Text
View/download PDF

41. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial

Author

Peyrade, Frédéric, Jardin, Fabrice, Thieblemont, Catherine, Thyss, Antoine, Emile, Jean-François, Castaigne, Sylvie, Coiffier, Bertrand, Haioun, Corinne, Bologna, Serge, Fitoussi, Olivier, Lepeu, Gérard, Fruchart, Christophe, Bordessoule, Dominique, Blanc, Michel, Delarue, Richard, Janvier, Maud, Salles, Bruno, André, Marc, Fournier, Marion, Gaulard, Philippe, and Tilly, Hervé

Published
2011
Full Text
View/download PDF

42. Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA)

Author

Bachy, Emmanuel, primary, Camus, Vincent, additional, Thieblemont, Catherine, additional, Sibon, David, additional, Casasnovas, René-Olivier, additional, Ysebaert, Loïc, additional, Damaj, Gandhi, additional, Guidez, Stéphanie, additional, Pica, Gian Matteo, additional, Kim, Won Seog, additional, Lim, Soon Thye, additional, André, Marc, additional, García-Sancho, Alejandro Martín, additional, Penarrubia, Maria Jesus, additional, Staber, Philipp B., additional, Trotman, Judith, additional, Hüttmann, Andreas, additional, Stefoni, Vittorio, additional, Re, Alessandro, additional, Gaulard, Philippe, additional, Delfau-Larue, Marie-Helene, additional, de Leval, Laurence, additional, Meignan, Michel, additional, Li, Ju, additional, Morschhauser, Franck, additional, and Delarue, Richard, additional

Published
2022
Full Text
View/download PDF

43. Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC

Author

Touzeau, Cyrille, Leux, Christophe, Bouabdallah, Reda, Roussel, Murielle, Delarue, Richard, Bouabdallah, Krimo, Thieblemont, Catherine, Cacheux, Victoria, Cartron, Guillaume, Compain, Laetitia, Gyan, Emmanuel, Morschhauser, Franck, Casasnovas, Olivier, Moles, Marie-Pierre, Michallet, Anne-Sophie, Gressin, Remy, Damaj, Gandhi, Rose, Christian, Sirvent, Anne, Hermine, Olivier, Mohty, Mohamad, Milpied, Noel, and Le Gouill, Steven

Published
2014
Full Text
View/download PDF

44. Durvalumab as monotherapy and in combination therapy in patients with lymphoma or chronic lymphocytic leukemia: The FUSION NHL 001 trial.

Author

Casulo, Carla, Santoro, Armando, Cartron, Guillaume, Ando, Kiyoshi, Munoz, Javier, Le Gouill, Steven, Izutsu, Koji, Rule, Simon, Lugtenburg, Pieternella, Ruan, Jia, Arcaini, Luca, Casadebaig, Marie‐Laure, Fox, Brian, Kilavuz, Nurgul, Rettby, Nils, Dell'Aringa, Justine, Taningco, Lilia, Delarue, Richard, Czuczman, Myron, and Witzig, Thomas

Published
2023
Full Text
View/download PDF

49. Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA).

Author

UCL - (MGD) Service d'hématologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, Bachy, Emmanuel, Camus, Vincent, Thieblemont, Catherine, Sibon, David, Casasnovas, René-Olivier, Ysebaert, Loïc, Damaj, Gandhi, Guidez, Stéphanie, Pica, Gian Matteo, Kim, Won Seog, Lim, Soon Thye, André, Marc, García-Sancho, Alejandro Martín, Penarrubia, Maria Jesus, Staber, Philipp B, Trotman, Judith, Hüttmann, Andreas, Stefoni, Vittorio, Re, Alessandro, Gaulard, Philippe, Delfau-Larue, Marie-Helene, de Leval, Laurence, Meignan, Michel, Li, Ju, Morschhauser, Franck, Delarue, Richard, UCL - (MGD) Service d'hématologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, Bachy, Emmanuel, Camus, Vincent, Thieblemont, Catherine, Sibon, David, Casasnovas, René-Olivier, Ysebaert, Loïc, Damaj, Gandhi, Guidez, Stéphanie, Pica, Gian Matteo, Kim, Won Seog, Lim, Soon Thye, André, Marc, García-Sancho, Alejandro Martín, Penarrubia, Maria Jesus, Staber, Philipp B, Trotman, Judith, Hüttmann, Andreas, Stefoni, Vittorio, Re, Alessandro, Gaulard, Philippe, Delfau-Larue, Marie-Helene, de Leval, Laurence, Meignan, Michel, Li, Ju, Morschhauser, Franck, and Delarue, Richard

Abstract

Romidepsin, a histone deacetylase inhibitor, has demonstrated activity in relapsed or refractory peripheral T-cell lymphoma (PTCL) as a single agent. Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) therapy is widely used as first-line treatment of PTCL; however, it has limited efficacy. Results from a phase Ib and II study showed the feasibility of combining romidepsin with CHOP (Ro-CHOP). This study is a randomized phase III study of Ro-CHOP versus CHOP in adult patients with previously untreated PTCL. All patients received CHOP in 3-week cycles for six cycles. Romidepsin, 12 mg/m, was administered intravenously over a 4-hour period on days 1 and 8 of each 3-week cycle for six cycles. The primary end point was progression-free survival (PFS) according to International Working Group 1999 criteria. Between January 2013 and December 2017, 421 patients were enrolled (Ro-CHOP, n = 211; CHOP, n = 210). The median PFS for Ro-CHOP versus CHOP was 12.0 months (95% CI, 9.0 to 25.8) versus 10.2 months (95% CI, 7.4 to 13.2) with a hazard ratio of 0.81 ( = .096). In the Ro-CHOP versus CHOP arms, the median overall survival was 51.8 versus 42.9 months and the objective response rate was 63% versus 60% with complete response plus unconfirmed complete response rates of 41% versus 37% ( > .1 in all comparisons), respectively. Grade 3 or 4 treatment-emergent adverse events occurring in ≥ 30% of patients in the Ro-CHOP arm included thrombocytopenia (50% 10% in the Ro-CHOP CHOP arms, respectively), neutropenia (49% 33%), anemia (47% 17%), and leukopenia (32% 20%). The addition of romidepsin to CHOP did not improve PFS, response rates, nor overall survival and increased the frequency for grade ≥ 3 treatment-emergent adverse events. Ro-CHOP does not represent a significant advance in the standard of care for patients with previously untreated PTCL.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results